UOC
BTMD icon

UBS O'Connor’s Biote Corp BTMD Stock Holding History

UBS O'Connor’s Portfolio BTMD Stock Details BTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-360,202
Closed -$3.54M – 30
2021
Q4 		$3.54M Buy
360,202
+9,647
+3% +$94.2K 0.03% 376
2021
Q3 		$3.41M Buy
350,555
+100,391
+40% +$972K 0.03% 402
2021
Q2 		$2.43M Buy
+250,164
New +$2.45M 0.02% 446

Other funds holding BTMD

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

UBS O'Connor's BTMD Position: Q1 2022 in Review

UBS O'Connor sold out of Biote Corp (BTMD) in Q1 2022, closing a stake of 360,202 shares — an estimated $3.54M sold.

UBS O'Connor first reported a position in BTMD in Q2 2021 and held it in 3 quarters. The position peaked at $3.54M in Q4 2021. 88 funds tracked by Wall St. Rank hold BTMD as of Q1 2022.

  • UBS O'Connor reported no remaining Biote Corp position as of Q1 2022 after selling out during the quarter.
  • UBS O'Connor sold 360,202 Biote Corp shares in Q1 2022, an estimated $3.54M.
  • UBS O'Connor first reported a position in Biote Corp in Q2 2021 and held it in 3 quarters.
  • UBS O'Connor's Biote Corp position peaked at $3.54M in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Biote Corp as of Q1 2022.

Based on UBS O'Connor's 13F filing for Q1 2022, filed 16 May 2022.